Health
“Ashwagandha is one of my favorite herbs for stress support. It helps reduce perceived stress and cortisol levels and can be truly relaxing to the body." (Instagram, @drjoshaxe, posted 2026-10-31)”
This post lists 6 claims. We checked item 1.
Plain restatementOral ashwagandha (Withania somnifera) supplementation lowers self-reported perceived stress and measured cortisol levels in humans, and produces a physiological relaxation effect.
General information only - not medical advice.
This claim is partly right but presented with far more confidence than the science supports. Real randomized trials exist, and several pooled analyses do find that ashwagandha lowers measured cortisol compared with a placebo, so that part has reasonable backing. The "perceived stress" part is where it breaks down, because one 2025 pooled analysis found a significant improvement while another found no significant effect at all, and formal quality ratings grade this evidence as low certainty due to small, short studies, most of them conducted in one country, with signs of publication bias. The post also names no dose, extract type, or duration, even though the NIH says the wide variation in preparations is exactly what makes it hard to give recommendations. It leaves out that long-term safety is unknown, that regulators in Germany warn pregnant and breastfeeding women and people with liver disease to avoid it, that it may affect thyroid function, and that Denmark banned it in supplements in 2023 over safety concerns. A lower cortisol reading is also not the same thing as feeling relaxed, and "truly relaxing to the body" is a phrase no study can test. The post is promotional content, which is worth keeping in mind when reading it. This is general information only and not medical advice.
Ashwagandha [drifted from the evidence:] is one of my favorite herbs for stress support. It helps reduce perceived stress and cortisol levels and [drifted from the evidence:] can be truly relaxing to the body." (Instagram, @drjoshaxe, posted 2026-10-31)
[added by the neutral restatement:] Oral ashwagandha [added by the neutral restatement:] (Withania somnifera) supplementation lowers self-reported perceived stress and [added by the neutral restatement:] measured cortisol levels [added by the neutral restatement:] in humans, and [added by the neutral restatement:] produces a physiological relaxation effect.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- Ashwagandha has been studied in multiple randomized placebo-controlled trials for stress, and those trials have been pooled in several meta-analyses. This is not an invented or fringe claim.
- The cortisol half of the claim is the better supported half. Multiple independent meta-analyses report a statistically significant reduction in cortisol versus placebo.
- Several meta-analyses, and the NIH Office of Dietary Supplements fact sheet, do report reductions in measured stress and anxiety scores versus placebo.
- Perceived Stress Scale and cortisol are both legitimate, validated outcome measures, so the claim is at least framed around the right endpoints.
- Exaggeration of certainty. The post asserts "it helps reduce" as settled fact. The strongest official source uses "may," and formal GRADE assessment rates the certainty of evidence for stress as low. Converting a low-certainty, heterogeneous body of evidence into a flat statement of effect overstates what is known.
- Omitted conflicting evidence on the specific outcome named. The post names "perceived stress," and that is precisely the endpoint where a 2025 meta-analysis found no significant effect. A reader is given one side of a split literature.
- Omitted qualifier on dose, extract and duration. No form, dose, or duration is specified, despite the trial evidence being dose-specific and extract-specific and the NIH explicitly noting that varying preparations make recommendations difficult. A reader cannot act on this claim in a way that matches the studied conditions.
- Subgroup and population generalization. The trial populations were largely adults in India already reporting elevated stress or diagnosed anxiety. The post addresses a general audience, including people who are not in that population.
- Biomarker presented as felt benefit. "Truly relaxing to the body" treats a cortisol change as equivalent to a subjective experience of relaxation. The literature does not reliably show the two move together, which is the entire point of the "cortisol down, perceived stress unchanged" meta-analysis.
- Unfalsifiable framing. "Can be truly relaxing to the body" is not a measurable endpoint and cannot be tested against any trial result. It functions as marketing language.
- Material safety omission. The post recommends a supplement that multiple national regulators have flagged for liver, thyroid and reproductive concerns, and that at least two European countries have restricted, without any caution, contraindication, or note that long-term safety is unknown.
- Whether ashwagandha reliably reduces perceived stress, as opposed to cortisol, remains genuinely unresolved. Two 2025 meta-analyses disagree on this directly.
- The true effect size cannot be pinned down. Heterogeneity is moderate to very high across analyses and publication bias has been documented, which means pooled estimates are likely unstable.
- Which specific extract, dose and duration produce benefit is not established, and the post does not specify any.
- Whether effects persist beyond roughly 8 to 12 weeks is unknown. No long-term trial evidence was found.
- Secondary claims in the same post were not investigated here: the stated cortisol to insulin to inflammation to accelerated aging chain, the characterization of magnesium as "the relaxation mineral," and the morning sunlight and circadian rhythm claims. These are noted as uninvestigated.
There is a real and reasonably sized body of randomized controlled trial evidence behind this claim, but it points in a more qualified direction than the post states. The strongest official source is cautious and uses conditional language. The NIH Office of Dietary Supplements states that research suggests ashwagandha extracts may lower stress, anxiety, and cortisol levels. A 2021 systematic review identified seven studies covering 491 adults, all from India, with either self-reported high stress and anxiety or a diagnosed anxiety disorder, randomized to ashwagandha or placebo for 6 to 8 weeks, and overall those studies found significantly reduced stress and anxiety on validated rating scales, reduced sleeplessness and fatigue, and reduced serum cortisol compared with placebo. On cortisol specifically, the evidence is the more consistent part. A 2025 meta-analysis reported a statistically significant reduction in cortisol of -1.16 µg/dL (95% CI -1.64 to -0.69, P < 0.001), with moderate heterogeneity (I² = 50.9%). On perceived stress, the evidence conflicts. The same 2025 analysis found no significant impact on perceived stress (SMD = -0.355, 95% CI -1.188 to 0.47, P = 0.40), and its conclusion was that findings support ashwagandha's role in lowering cortisol, while gaps remain regarding long-term safety, dosing, and effectiveness across diverse populations. A different 2025 meta-analysis reached the opposite conclusion on that outcome: it reported a significant effect in reducing both stress (Perceived Stress Scale, μ = -4.88, 95% CI -7.84 to -1.91, p = 0.0013) and cortisol (μ = -2.36, 95% CI -3.26 to -1.46, p < 0.0001) at 8 weeks of treatment. An earlier 2022 dose-response meta-analysis also found benefit: it reported significantly reduced anxiety (SMD -1.55, I² = 93.8%) and stress (SMD -1.75, I² = 83.1%) versus placebo, with a favorable dose-response effect on stress at 300 to 600 mg/day, though the heterogeneity figures are very high. Certainty of the evidence is formally rated as weak. A separate meta-analysis using GRADE found that quality of evidence ranged from very low for depression symptoms to low for anxiety symptoms, sleep quality and stress, with downgrading driven by the limited number of studies per pooled estimate, high heterogeneity, and bias threats related to blinding procedures, and the authors found evidence of publication bias.
Complete reasoning
The reply is formatted for pasting into the thread where the claim is circulating.